ISRCTN ISRCTN12929657
DOI https://doi.org/10.1186/ISRCTN12929657
Secondary identifying numbers 001
Submission date
04/08/2014
Registration date
08/09/2014
Last edited
06/05/2020
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
Paranoia is a mental condition where a person falsely believes that they are being persecuted by others and is deeply suspicious and mistrustful of those around them. Many paranoid patients live restricted lives; they find relationships difficult due to being so suspicious and unfriendly, suffer from social anxiety and tend to avoid all kinds of social occasions. Here, we want to see whether virtual reality technology helps to make paranoid patients feel more able to go outside and enjoy social occasions.

Who can participate?
All patients that experience fear and avoid going outside or travelling by public transportation, etc.

What does the study involve?
The patients are randomly allocated into one of two groups. Those in group 1 have up to 16 sessions of virtual reality exposure therapy over a 3 month period. Those in group 2 are placed on a waiting list for 6 months, after which they also receive the treatment. The amount of social participation (time spent with other people, including family, friends, colleagues and strangers) and feelings of paranoia experienced in social situations is measured. All participants are assessed at the start of the treatment, at the end of the treatment and 3 months after the treatment has ended.

What are the possible benefits and risks of participating?
There are no known serious risks. Some people feel sick (cyber illness) during the virtual reality exposure.

Where is the study run from?
VU University, Amsterdam (Netherlands) and the Parnassia Psychiatric Institute in the Hague (Netherlands)

When is study starting and how long is it expected to run for?
April 2014 to December 2015

Who is funding the study?
The NutsOhra Foundation (Netherlands)

Who is the main contact?
Professor Mark van der Gaag
m.vander.gaag@vu.nl

Contact information

Prof Mark van der Gaag
Scientific

van der Boechorststraat 1
Amsterdam
1081 BT
Netherlands

Phone +31 (0) 64 578 04 63
Email m.vander.gaag@vu.nl

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleThe effect of Virtual Reality Exposure Therapy (VRET) on social participation in people with a psychotic disorder: a multi-site randomized controlled trial
Study acronymVRET.P
Study hypothesisVirtual Reality Exposure Therapy will improve real life social participation in patients with a psychotic disorder experiencing paranoia and/or social anxiety symptoms.
Ethics approval(s)Medical Ethical Committee of VU Medical Center; 06/03/2014; NL45965.029.13 / 2014.015
ConditionPsychotic disorders with continuing social withdrawal
InterventionIn both arms treatment as usual will be provided for the psychotic disorder for which the person sought help. In the first experimental arm there will be a maximum of 16 sessions (over three months) of Virtual Reality Exposure Treatment with a trained CBT therapist aimed at improving social participation. Treatment duration is three months, patients will be followed-up at 3 months. The second arm entails a waiting list for a period of six month, after which these participants will also get the VRET treatment.
Intervention typeOther
Primary outcome measure1. Experience Sampling Method (ESM) on social participation.
2. Objective social participation is expressed as the amount of time spend with other people and the type of company (for example family, friends, colleagues or strangers).
3. Subjective social participation is expressed as momentary paranoia, perceived social threat and event stress as experienced in social situations.

All measures are measured at baseline, at end of treatment at 3 months, and at follow-up at 6 months.
Secondary outcome measures1. Depression (BDI-II)
2. Stigmatisation and schemata (ISMI, BCSS)
3. Paranoia (GPTS)
4. Social interaction anxiety (SIAS)
5. Cognitive biases (DACOBS)
6. Safety behavior (Safety Behavior Questionnaire – persecutory delusions)
7. Quality of life and cost-effectiveness (MANSA,TIC-P)
8. Presence and cyber sickness (SSQ, IPQ), measured at month 1 and at month 2 during treatment.
9. Psychosis (Positive and Negative symptom scales)
10. Social functioning (Social and Occupational Functioning Assessment Scales)
Overall study start date01/04/2014
Overall study end date31/12/2015

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants160
Total final enrolment116
Participant inclusion criteria1. Aged 18 to 65 years, either sex
2. Fullfilling diagnostic criteria for a psychotic disorder
3. Experiencing at least mild paranoia and/or social anxiety as measured with the Green et al. Paranoid Thought Scales (GPTS) and Social Interaction Anxiety Scale (SIAS)
Participant exclusion criteria1. IQ under 70
2. Insufficient command of the Dutch language
3. Epilepsy
Recruitment start date01/04/2014
Recruitment end date31/12/2015

Locations

Countries of recruitment

  • Netherlands

Study participating centre

van der Boechorststraat 1
Amsterdam
1081 BT
Netherlands

Sponsor information

NutsOhra Foundation (Fonds NutsOhra) (Netherlands)
Other

Amstelplein 6
Amsterdam
1096 BC
Netherlands

Phone +31 (0)20 594 96 90
Email info@fondsnutsohra.nl
Website http://www.fondsnutsohra.nl
ROR logo "ROR" https://ror.org/04ev7sy32

Funders

Funder type

Other

Fonds NutsOhra (Netherlands)
Private sector organisation / Other non-profit organizations
Alternative name(s)
NutsOhra Foundation, NutsOhra Fund, Stichting Nuts Ohra
Location
Netherlands

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 13/01/2016 Yes No
Results article cybersickness results 01/03/2018 18/02/2019 Yes No
Results article main results 01/03/2018 18/02/2019 Yes No
Results article cost-effectiveness results 05/05/2020 06/05/2020 Yes No

Editorial Notes

06/05/2020: Publication reference and total final enrolment added.
18/02/2019: Publication references added.
15/01/2016: Publication reference added.